A key message delivered by an expert emphasized a shift in clinical decision-making for ADHD treatment. The recommendation is to move from a risk/no-risk perspective to a risk-risk analysis, balancing the largely reassuring risks of medication exposure against the known risks of under-treating or not treating ADHD in this population.
Comorbidity is a significant clinical concern, as women with ADHD frequently experience co-occurring mood and anxiety disorders. The postpartum period is noted to carry substantial risk for exacerbating these comorbid conditions, driven by significant hormonal transitions, sleep disruption, and increased executive functioning demands.
Clinicians are advised to rethink treatment decisions for reproductive-age women, stressing the importance of proactive planning. This approach involves thoughtful and intentional planning for pregnancy and postpartum, integrating non-pharmacologic therapies with pharmacotherapies, especially in cases of moderate to severe ADHD, to ensure comprehensive patient care.
Regarding medication use, the guidance states that if ADHD pharmacotherapy is essential for an individual's daily functioning, its continuation during pregnancy is appropriate. These discussions are best held well in advance of pregnancy. Furthermore, a collaborative communication process involving pediatricians, obstetricians/gynecologists, and psychotherapists is encouraged.
Clinicians should establish baselines and adopt a holistic view, incorporating psychotherapies, coaching, and mindfulness-based interventions.